Zejula (niraparib) — Cigna

Ovarian, Fallopian Tube, or Primary Peritoneal Cancer – Maintenance Therapy

Initial criteria

Patient age ≥ 18 years
Patient is in complete or partial response after a platinum-based chemotherapy regimen
Patient meets ONE of the following (i or ii):
i. Patient meets BOTH of the following (a and b):
a) Patient has recurrent disease
b) Patient has a BRCA mutation
OR
ii. Patient meets BOTH of the following (a and b):
a) Patient is in complete or partial response to first-line primary treatment
b) Patient has homologous recombination deficiency (HRD)-positive disease

1 year